Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (223)
  2. Journal Article (82)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (5)
  6. Editorial (4)
  7. Guidelines (3)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (171)
  2. Department of Medicine (168)
  3. Center for Hematologic Malignancies (161)
  4. Graduate Medical Education (151)
  5. Myeloma (149)
  6. GME, Medicine (142)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Kylee Maclachlan (127)
  3. Sham Mailankody (113)
  4. Urvi Shah (110)
  5. Carlyn Rose Tan (105)
  6. Neha Korde (103)

More People

Years
  1. 2025 (42)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (110)
  2. Clinical Lymphoma, Myeloma and Leukemia (81)
  3. Journal of Clinical Oncology (32)
  4. Blood Cancer Journal (16)
  5. Blood Advances (15)
  6. British Journal of Haematology (8)

More Publications

Publishers
  1. American Society of Hematology (125)
  2. Elsevier Inc. (94)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (24)
  5. Elsevier Science, Inc. (10)
  6. John Wiley & Sons (9)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Progression-free survival of daratumumab vs bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: TAURUS chart review study
    Meeting Abstract

    Gordan, L.; Tan, C. R.; Vescio, R.; Ye, J. C.; Schinke, C.; Medhekar, R.; Fu, A. Z.; Lafeuille, M. H.; Thompson-Leduc, P.; Khare, V.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Lin, Y.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the MajesTEC-1 study
    Meeting Abstract

    Usmani, S. Z.; Karlin, L.; Benboubker, L.; Nahi, H.; San-Miguel, J.; Trancucci, D.; Qi, K.; Stephenson, T.; Puchalt, A. P.; Chastain, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy outcomes and characteristics of patients with multiple myeloma (mm) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1
    Meeting Abstract

    Munshi, N.; Pavia, B.; Martin, T.; Usmani, S.; Lin, Y.; Schecter, J.; Jackson, C.; Madduri, D.; Zudaire, E.; Yeh, T. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab plus Lenalidomide/dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA update
    Meeting Abstract

    Basu, S.; Kumar, S. K.; Moreau, P.; Bahlis, N.; Facon, T.; Plesner, T.; Orlowski, R. Z.; Nahi, H.; Hulin, C.; Quach, H.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Frontline treatment for high-risk multiple myeloma: Personalized?
    Meeting Abstract

    Usmani, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • The role of chimeric antigen receptor T-cell therapy in the era of bispecific antibodies
    Review

    Nath, K.; Mailankody, S.; Usmani, S. Z.
    Hematology/Oncology Clinics of North America (2023)

    Fulltext@MSK | Save
  • Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial
    Journal Article

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Chari, A.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Population pharmacokinetics and exposure–response with teclistamab in patients with relapsed/refractory multiple myeloma: Results from MajesTEC-1
    Journal Article

    Miao, X.; Wu, L. S.; Lin, S. X. W.; Xu, Y.; Chen, Y.; Iwaki, Y.; Kobos, R.; Stephenson, T.; Kemmerer, K.; Uhlar, C. M.; more...
    Targeted Oncology (2023)

    Fulltext@MSK | Save
  • Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES)
    Meeting Abstract

    Joseph, J.; Tang, L.; Hillengass, J.; Landgren, O.; Usmani, S. Z.; Lesokhin, A. M.; Moysich, K. B.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save